title: Intravitreal Dexamethasone for the Treatment of CMO Associated with Refractory Sclerouveitis.
abstract: OBJECTIVE
  To assess the efficacy and tolerability of intravitreal dexamethasone 0.7 mg sustained-release insert (Ozurdex®) in patients with sclerouveitis and recurrent cystoid macula edema (CMO) refractory to treatment.
  
  
  METHODS
  Interventional retrospective case series of five patients receiving 13 intravitreal dexamethasone inserts.
  
  
  RESULTS
  Three of five patients presented with an associated systemic disorder, whereas two patients had idiopathic sclerouveitis. All patients received immunosuppressive therapy. The CRT mean (SD) decreased in all eyes from 428 μm (137) (baseline) to 327 μm (149) (1 month), 342 μm (155) (3 months), 297 μm (99) (6 months) and reduced scleral inflammation. No morphologic adverse changes were noted, in particular, no scleral melting or necrosis occurred.
  
  
  CONCLUSIONS
  Intravitreal dexamethasone may be an effective and safe therapeutic option in sclerouveitis with otherwise treatment-resistant CMO. It resolves not only CMO, but also provides a reduction of scleral inflammation and ocular pain. Nonetheless, adequate immunosuppressive treatment of an underlying disease must ensue.
authors.affiliation: a Department of Ophthalmology , University Medicine Charité, Campus Virchow Clinic , Berlin , Germany.
authors.forename: Dominika
authors.initials: D
authors.lastname: Pohlmann
authors.affiliation: a Department of Ophthalmology , University Medicine Charité, Campus Virchow Clinic , Berlin , Germany.
authors.forename: Sibylle
authors.initials: S
authors.lastname: Winterhalter
authors.affiliation: a Department of Ophthalmology , University Medicine Charité, Campus Virchow Clinic , Berlin , Germany.
authors.forename: Uwe
authors.initials: U
authors.lastname: Pleyer
mesh_terms: D000328:Adult; D003907:Dexamethasone / Q000008:administration & dosage*; D004343:Drug Implants; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015423:Scleritis / Q000150:complications / Q000188:drug therapy*; D041623:Tomography, Optical Coherence; D014605:Uveitis / Q000150:complications / Q000188:drug therapy*; D014792:Visual Acuity
chemical_list: D004343:Drug Implants; D005938:Glucocorticoids; D003907:Dexamethasone
keywords: CMO; intravitreal dexamethasone; scleritis; systemic disease; uveitis